Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Mostrar otras versiones (1)

Aim: Pemafibrate is a highly selective agonist for peroxisome proliferator-activated receptor (PPAR)-α, a key regulator of lipid and glucose metabolism. We compared the efficacy and safety of pemafibrate with those of bezafibrate, a nonselective PPAR-α agonist. Methods: In this randomized crossover...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Akihiro, Kagaya, Yuta, Saito, Hiroki, Kanazawa, Masanori, Sato, Kenjiro, Miura, Masanobu, Kondo, Masateru, Endo, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164592/
https://www.ncbi.nlm.nih.gov/pubmed/35768226
http://dx.doi.org/10.5551/jat.63659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164592/
https://www.ncbi.nlm.nih.gov/pubmed/35768226
http://dx.doi.org/10.5551/jat.63659

Ejemplares similares